Publicacions en què col·labora amb Francisco Sogorb Garri (62)

2016

  1. Is the ORBIT bleeding risk score superior to the HAS-BLED score in anticoagulated atrial fibrillation patients?

    Circulation Journal, Vol. 80, Núm. 10, pp. 2102-2108

  2. Long-term predictors of thromboembolic events in nonvalvular atrial fibrillation patients undergoing electrical cardioversion

    Circulation Journal, Vol. 80, Núm. 3, pp. 605-612

  3. Sport, health and sudden death

    International Journal of Cardiology, Vol. 221, pp. 230-231

  4. The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion

    International Journal of Cardiology, Vol. 217, pp. 42-48

2015

  1. Effects of body mass index on the lipid profile and biomarkers of inflammation and a fibrinolytic and Prothrombotic state

    Journal of Atherosclerosis and Thrombosis, Vol. 22, Núm. 6, pp. 610-617

2013

  1. Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting

    Age and Ageing, Vol. 42, Núm. 1, pp. 70-75

2012

  1. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?

    Circulation: Cardiovascular Interventions, Vol. 5, Núm. 4, pp. 459-466

2011

  1. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization

    Chest, Vol. 139, Núm. 6, pp. 1402-1409

2010

  1. The prognostic value of biomarkers after a premature myocardial infarction

    International Journal of Cardiology, Vol. 143, Núm. 3, pp. 249-254

2009

  1. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation

    European Heart Journal, Vol. 30, Núm. 8, pp. 932-939

  2. Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers

    International Journal of Cardiology, Vol. 136, Núm. 2, pp. 222-225

  3. ¿Existe un efecto beneficioso a largo plazo con el tratamiento con marcapasos de la miocardiopatía hipertrófica obstructiva severa?

    Revista Espanola de Cardiologia, Vol. 62, Núm. 11, pp. 1233-1239

2008

  1. Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. Implications for Bleeding Risk and Prognosis

    Journal of the American College of Cardiology, Vol. 51, Núm. 8, pp. 818-825

  2. Premature myocardial infarction: Clinical profile and angiographic findings

    International Journal of Cardiology, Vol. 126, Núm. 1, pp. 127-129

2007

  1. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: Implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels

    Journal of Internal Medicine, Vol. 262, Núm. 6, pp. 651-658

  2. Common carotid artery intima-media thickness and intracranial pulsatility index in non-ST-elevation acute coronary syndromes

    Cerebrovascular Diseases, Vol. 24, Núm. 4, pp. 338-342

  3. Plasma angiogenin levels in acute coronary syndromes: Implications for prognosis

    European Heart Journal, Vol. 28, Núm. 24, pp. 3006-3011

2006

  1. Antiplatelet versus anticoagulant therapies in advanced age: An unfinished task

    International Journal of Cardiology, Vol. 110, Núm. 2, pp. 271-272

  2. Atrial stunning as predictor of early relapse into atrial fibrillation after cardioversion

    International Journal of Cardiology, Vol. 110, Núm. 3, pp. 427-428

  3. Desfibrilador automático en la miocardiopatía hipertrófica. Experiencia de 3 centros

    Revista Espanola de Cardiologia, Vol. 59, Núm. 6, pp. 537-544